The Microbiota-Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders.
- 1Department of Physiology & Cell Biology School of Medicine University of Nevada Reno Nevada USA unlv.edu.
- 2Sir Salimullah Medical College Dhaka Bangladesh.
- 3Department of Pharmacy National Model College for Advance Learning Tribhuvan University Kathmandu Nepal tribhuvan-university.edu.np.
Abstract
The gut microbiota (GM) modulates host energy balance, glucose-lipid metabolism, and enteroendocrine signaling through metabolite-receptor axes that include short-chain fatty acids (SCFAs) acting on FFAR2/FFAR3 (GPR43/GPR41), microbially transformed bile acids signaling via FXR/TGR5, and amino-acid/choline-derived compounds such as imidazole propionate (ImP) and trimethylamine N-oxide (TMAO). These pathways regulate incretin biology (GLP-1/PYY), insulin sensitivity, hepatic glucose output, adipose lipolysis, and appetite, thereby shaping risk and progression of Type 2 diabetes mellitus (T2DM), obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and related conditions. Here, we synthesize mechanistic and translational evidence, highlight bidirectional drug-microbiome interactions (GLP-1 receptor agonists), and review interventions spanning diet, pre/probiotics, fecal microbiota transplantation (FMT), and pharmacologic targeting of bile-acid and SCFA pathways. Together, these findings support precision strategies that profile GM-metabolite signatures (e.g., SCFAs, secondary bile acids, and ImP TMAO) to guide prevention and therapy in metabolic and gastrointestinal disease.
Related
- Microbiota–host crosstalk in ulcerative colitis: mechanistic evidence and translational prospects for traditional Chinese medicine
- Disease-specific gut microbiota–metabolite–immune networks in hematologic disorders: mechanisms, causal support, and translational strategies
- Faecalibacterium prausnitzii in neurological disorders: mechanistic links and therapeutic potential along the microbiota–gut–brain axis
- Evaluating traditional Chinese medicine modulation of the gut microbiota–bile acid axis in metabolic and inflammatory diseases: mechanistic evidence and translational priorities
- Gut Microbiota Signaling Axes as Candidate Therapeutic Targets in Type 2 Diabetes Mellitus: Mechanistic Crosstalk and Translational Challenges
BibTeX
@article{akif2026microbiotametabolism,
title = {{The Microbiota-Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders.}},
author = {Adnan Akif and Nigar Sultana and Ishtyaque Mikrani},
journal = {International journal of endocrinology},
year = {2026},
month = nov,
doi = {10.1155/ije/7761643},
url = {https://europepmc.org/article/MED/43011569},
note = {CC BY},
}
RIS
TY - JOUR
TI - The Microbiota-Metabolism Axis: Mechanistic Insights and Translational Targets Across Diabetes and Gastrointestinal Disorders.
AU - Adnan Akif
AU - Nigar Sultana
AU - Ishtyaque Mikrani
PY - 2026
DA - 2026/11/09
JO - International journal of endocrinology
DO - 10.1155/ije/7761643
UR - https://europepmc.org/article/MED/43011569
AB - The gut microbiota (GM) modulates host energy balance, glucose-lipid metabolism, and enteroendocrine signaling through metabolite-receptor axes that include short-chain fatty acids (SCFAs) acting on FFAR2/FFAR3 (GPR43/GPR41), microbially transformed bile acids signaling via FXR/TGR5, and amino-acid/choline-derived compounds such as imidazole propionate (ImP) and trimethylamine N-oxide (TMAO). These pathways regulate incretin biology (GLP-1/PYY), insulin sensitivity, hepatic glucose output, adipose lipolysis, and appetite, thereby shaping risk and progression of Type 2 diabetes mellitus (T2DM), obesity, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and related conditions. Here, we synthesize mechanistic and translational evidence, highlight bidirectional drug-microbiome interactions (GLP-1 receptor agonists), and review interventions spanning diet, pre/probiotics, fecal microbiota transplantation (FMT), and pharmacologic targeting of bile-acid and SCFA pathways. Together, these findings support precision strategies that profile GM-metabolite signatures (e.g., SCFAs, secondary bile acids, and ImP TMAO) to guide prevention and therapy in metabolic and gastrointestinal disease.
SN - 1687-8337
SN - 1687-8345
ER -